Innovation Field In-Vitro Diagnostics, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, 70569 Stuttgart, Germany.
Interfaculty Graduate School of Infection Biology and Microbiology (IGIM), Eberhard Karls University Tuebingen, 72076 Tuebingen, Germany.
Int J Mol Sci. 2024 May 17;25(10):5463. doi: 10.3390/ijms25105463.
Sepsis is a life-threatening syndrome triggered by infection and accompanied by high mortality, with antimicrobial resistances (AMRs) further escalating clinical challenges. The rapid and reliable detection of causative pathogens and AMRs are key factors for fast and appropriate treatment, in order to improve outcomes in septic patients. However, current sepsis diagnostics based on blood culture is limited by low sensitivity and specificity while current molecular approaches fail to enter clinical routine. Therefore, we developed a suppression PCR-based selective enrichment sequencing approach (SUPSETS), providing a molecular method combining multiplex suppression PCR with Nanopore sequencing to identify most common sepsis-causative pathogens and AMRs using plasma cell-free DNA. Applying only 1 mL of plasma, we targeted eight pathogens across three kingdoms and ten AMRs in a proof-of-concept study. SUPSETS was successfully tested in an experimental research study on the first ten clinical samples and revealed comparable results to clinical metagenomics while clearly outperforming blood culture. Several clinically relevant AMRs could be additionally detected. Furthermore, SUPSETS provided first pathogen and AMR-specific sequencing reads within minutes of starting sequencing, thereby potentially decreasing time-to-results to 11-13 h and suggesting diagnostic potential in sepsis.
脓毒症是一种由感染引发的危及生命的综合征,伴有高死亡率,而抗菌药物耐药性(AMRs)进一步加剧了临床挑战。快速、可靠地检测病原体和 AMRs 是快速、适当治疗的关键因素,以改善脓毒症患者的预后。然而,目前基于血液培养的脓毒症诊断方法存在灵敏度和特异性低的局限性,而目前的分子方法则无法进入临床常规。因此,我们开发了一种基于抑制 PCR 的选择性富集测序方法(SUPSETS),提供了一种分子方法,将多重抑制 PCR 与纳米孔测序相结合,使用血浆无细胞 DNA 来鉴定最常见的脓毒症病原体和 AMRs。该方法仅应用 1 毫升血浆,在一项针对前 10 个临床样本的概念验证研究中针对三个界的 8 种病原体和 10 种 AMRs 进行了靶向检测。SUPSETS 在一项关于前 10 个临床样本的实验研究中得到了成功验证,其结果与临床宏基因组学相当,但明显优于血液培养。此外,SUPSETS 还可以额外检测到几种临床相关的 AMRs。此外,SUPSETS 可以在开始测序后的几分钟内提供病原体和 AMR 特异性的测序读长,从而有可能将结果时间缩短至 11-13 小时,并提示在脓毒症中具有诊断潜力。